Long‐term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open‐label phase 3 results

This phase 3, multicenter, open‐label single‐arm study evaluated adalimumab (ADA) in Japanese patients with moderate to severe hidradenitis suppurativa (HS). Fifteen patients received ADA 160 mg s.c. at week 0, 80 mg at week 2 and 40 mg at week 4 and every week thereafter. At any time after week 52,...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Akimichi, Takahashi, Hidetoshi, Ozawa, Kentaro, Imafuku, Shinichi, Takekuni, Nakama, Takahashi, Kenzo, Matsuyama, Takashi, Okubo, Yukari, Zhao, Yiwei, Kitamura, Susumu, Takei, Keiko, Yokoyama, Masayuki, Hayashi, Nobukazu, Terui, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821142/
https://www.ncbi.nlm.nih.gov/pubmed/33029861
http://dx.doi.org/10.1111/1346-8138.15605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821142/
https://www.ncbi.nlm.nih.gov/pubmed/33029861
http://dx.doi.org/10.1111/1346-8138.15605

Ejemplares similares